Hero

Letter to Shareholders

1

Letter to Shareholders

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

2

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

3

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process

4

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Letter to Shareholders - January 2020

Letter to Shareholders - January 2020

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Discover all news

Carousel

Social Feed

Peggy Sotiropoulou, R&D Director at Celyad will give a talk tomorrow at the CAR-T Congress EU in London! $CYAD https://t.co/NVlj3KazIL

6 hours ago

Peggy Sotiropoulou, R&D Director at Celyad will give a talk tomorrow at the CAR-T Congress EU in London! $CYAD https://t.co/NVlj3KazIL

Discover Celyad's Letter to Shareholders ! Available in English, French and Dutch $CYAD https://t.co/fJ6hW9oHoW

14 hours ago

Discover Celyad's Letter to Shareholders ! Available in English, French and Dutch $CYAD https://t.co/fJ6hW9oHoW

@LatereJp , COO at Celyad is speaking tomorrow at Vein-to-Vein Europe ! https://t.co/fTONRsUDPH

1 day ago

@LatereJp , COO at Celyad is speaking tomorrow at Vein-to-Vein Europe ! https://t.co/fTONRsUDPH

RT @BioVoxBelgium: Interested in the European #biotech business? This @Labiotech_eu list highlights companies to keep an eye on over the ne…

1 week ago

RT @BioVoxBelgium: Interested in the European #biotech business? This @Labiotech_eu list highlights companies to keep an eye on over the ne…

Peggy Sotiropoulou, R&D Director at Celyad will give a talk tomorrow at the CAR-T Congress EU in London! $CYAD https://t.co/NVlj3KazIL

6 hours ago

Peggy Sotiropoulou, R&D Director at Celyad will give a talk tomorrow at the CAR-T Congress EU in London! $CYAD https://t.co/NVlj3KazIL

Discover Celyad's Letter to Shareholders ! Available in English, French and Dutch $CYAD https://t.co/fJ6hW9oHoW

14 hours ago

Discover Celyad's Letter to Shareholders ! Available in English, French and Dutch $CYAD https://t.co/fJ6hW9oHoW

@LatereJp , COO at Celyad is speaking tomorrow at Vein-to-Vein Europe ! https://t.co/fTONRsUDPH

1 day ago

@LatereJp , COO at Celyad is speaking tomorrow at Vein-to-Vein Europe ! https://t.co/fTONRsUDPH

RT @BioVoxBelgium: Interested in the European #biotech business? This @Labiotech_eu list highlights companies to keep an eye on over the ne…

1 week ago

RT @BioVoxBelgium: Interested in the European #biotech business? This @Labiotech_eu list highlights companies to keep an eye on over the ne…